Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Free Research Reports on APL, BLRX, INTC and OCZ Issued by the Bedford Report

BLRX, INTC
Free Research Reports on APL, BLRX, INTC and OCZ Issued by the Bedford Report
http://media.marketwire.com/attachments/201211/53317_equitynewscircuit-logo-final.jpghttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1008456&ProfileId=051205&sourceType=1

NEW YORK, NY -- (Marketwired) -- 04/18/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Atlas Pipeline Partners, L.P. (NYSE: APL) shares declined 3.44 percent on more than six times the average daily volume Wednesday to close at $34.24. The company has announced that it has agreed to acquire TEAK Midstream, L.L.C., a privately owned midstream operator, for $1 billion in cash.

Find out more about Atlas Pipeline Partners including full access to the free equity report at: www.BedfordReport.com/APL

Bioline RX Ltd. (NASDAQ: BLRX) shares hit a high of $2.00 a share Wednesday before settling to close at $1.88, an increase of 3.30 percent. The company has reported positive results from a Phase IIa trial of BL-7040 for the treatment of ulcerative colitis, a form of inflammatory bowel disease.

Find out more about Bioline RX including full access to the free equity report at: www.BedfordReport.com/BLRX

Intel Corporation (NASDAQ: INTC) shares traded in the range of $21.57 to $22.14 a share before settling to close at $21.93. The company reported revenues of $12.6 billion for the first quarter of 2013, an increase of 7 percent sequentially and a decline of 3 percent annually.

Find out more about Intel including full access to the free equity report at: www.BedfordReport.com/INTC

OCZ Technology Group Inc. (NASDAQ: OCZ) shares surged 26.02 percent on volume of over 5.0 million shares traded Wednesday to close at $1.55 a share. The company recently reported that revenues for the fiscal fourth quarter are expected to be between $65 million and $70 million. According to FactSet, the average analyst estimate called for revenues of $89.3 million.

Find out more about OCZ Technology Group including full access to the free equity report at: www.BedfordReport.com/OCZ

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information:

Equity News Circuit
Email Contact